clinical trial · NCT07024563
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Alexion Pharmaceuticals, Inc.·phase3·recruiting·n = 24
IgANIgAVNImmunoglobulin A NephropathyImmunoglobulin A Vasculitis Associated NephritisHenoch-schonlein Purpura NephritisIgA VasculitisRavulizumab
brief summary
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
started
Jun 14, 2025
primary completion
Jul 12, 2028
completion
Nov 27, 2029
last updated
Mar 17, 2026
official title
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol